Asset Details
Do you wish to reserve the book?
Apixaban in Patients with Atrial Fibrillation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Apixaban in Patients with Atrial Fibrillation
Do you wish to request the book?
Apixaban in Patients with Atrial Fibrillation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Apixaban in Patients with Atrial Fibrillation
2011
Overview
In this trial, the factor Xa inhibitor apixaban was shown to reduce the risk of stroke or systemic embolism, as compared with aspirin, without a significant increase in the risk of major bleeding. Apixaban is an alternative to aspirin for patients who cannot take warfarin..
Atrial fibrillation is a common arrhythmia that increases the risk of stroke.
1
Vitamin K antagonist therapy is more effective than aspirin for the prevention of stroke in patients with atrial fibrillation, but its use is limited by a narrow window for a therapeutic benefit and by the need for lifelong coagulation monitoring owing to a marked variation in its effect both from one patient to another and within the individual patient.
2
Maintaining the international normalized ratio (INR) in the therapeutic range is challenging and for many patients is achieved less than 60% of the time — a finding that counteracts . . .
Publisher
Massachusetts Medical Society
